BioSpace News Archive

Frontier Medicines, Corp., a precision medicine company drugging challenging protein targets to develop breakthrough medicines that change the course of human diseases, today announced the appointment of David M. Goldstein, Ph.D., to its Board of Directors.

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the publication of a peer-reviewed paper in eLife, a science journal, entitled,

Women and Infants Hospital in Providence, Rhode Island, has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the U.S. to test the Vesair Bladder Control Balloon procedure.

Agilent Technologies Inc. (NYSE: A) announces that Octagon Therapeutics has been awarded an Agilent Golden Ticket at LabCentral

Biomax Informatics today announced the development of a novel knowledge management and database solution NeuroCONNECT for EBRAINS, the digital research infrastructure created by the EU-funded Human Brain Project.

Can-Fite BioPharma Ltd. announced that the six existing distribution agreements it has signed for its advanced stage drug candidates Piclidenoson and Namodenoson in select territories have remaining potential milestone payments of up to approximately $130 million plus double digit royalties on net sales following regulatory approval.

Better Therapeutics, Inc., a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, announced the appointments of Andrew Armanino and Geoffrey Parker to its board of directors.

Since 1979, Huntleigh, a member of the Arjo family, has strived to provide patients and the professionals who care for them, innovative solutions that improve outcomes and enhance patient well being, from the safe delivery of a new life to the day-to-day quality of life.

VolitionRx Limited announced the appointment, effective May 1, 2021, of Dr. Tom Butera DVM, to the position of Chief Executive Officer, Volition Veterinary Diagnostics Development LLC, assuming such role from Dr. Gaetan Michel who continues to serve as Chief Operating Officer of Volition and Chief Executive Officer of Belgian Volition.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines, today announced that Julia Wang has been appointed as Chief Financial Officer, effective June 30, 2021.